Published in J Clin Oncol on October 01, 1998
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst (2009) 2.77
The Shipman inquiry: implications for the public's trust in doctors. Br J Gen Pract (2000) 2.55
Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch Arztebl Int (2010) 1.64
The risk of bias from omitted research. BMJ (2000) 1.43
Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer (2003) 1.40
The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging (2004) 1.33
Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012. Geburtshilfe Frauenheilkd (2013) 1.14
Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int J Breast Cancer (2013) 1.05
Past, present, and future challenges in breast cancer treatment. J Clin Oncol (2014) 1.04
Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy. BMC Cancer (2008) 1.04
Present and future evolution of advanced breast cancer therapy. Breast Cancer Res (2010) 1.01
Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer (2011) 0.98
From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs (2006) 0.97
Combination drug delivery approaches in metastatic breast cancer. J Drug Deliv (2012) 0.97
Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity. Biomaterials (2012) 0.97
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer (2004) 0.95
US Food and Drug Administration approval overview in metastatic breast cancer. J Clin Oncol (2012) 0.89
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Drug Des Devel Ther (2015) 0.87
Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians. Ther Adv Med Oncol (2013) 0.87
Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype. BMC Cancer (2010) 0.86
Whither high-dose chemotherapy in breast cancer? Breast Cancer Res (2000) 0.86
Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial. Br J Cancer (2002) 0.86
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy. Br J Cancer (2004) 0.85
Dose-dense epirubicin and cyclophosphamide followed by docetaxel as adjuvant chemotherapy in node-positive breast cancer. Int J Breast Cancer (2013) 0.84
First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study. BMC Cancer (2005) 0.83
Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat (2007) 0.83
Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. Br J Cancer (2006) 0.83
Breast cancer (metastatic). BMJ Clin Evid (2007) 0.82
Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines. Curr Oncol (2015) 0.82
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wien Klin Wochenschr (2010) 0.82
30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study. Lancet Oncol (2016) 0.81
A comparative analysis on the efficacy and safety of intaxel® and taxol® in advanced metastatic breast cancer. J Clin Diagn Res (2013) 0.81
Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients? Ther Adv Med Oncol (2016) 0.81
Feasibility and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic or recurrent breast cancer. Int J Clin Oncol (2013) 0.80
Role of taxane and anthracycline combination regimens in the management of advanced breast cancer: a meta-analysis of randomized trials. Medicine (Baltimore) (2015) 0.80
Triple-negative breast cancer: multipronged approach, single-arm pilot phase II study. Cancer Med (2012) 0.79
Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401). Int J Clin Oncol (2014) 0.79
A decade of progress in cancer research. BMC Cancer (2011) 0.79
Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer. Invest New Drugs (2009) 0.78
Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. Br J Cancer (2004) 0.78
miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Oncotarget (2016) 0.78
Breast cancer (metastatic). BMJ Clin Evid (2010) 0.77
The mitochondrial transport protein SLC25A43 affects drug efficacy and drug-induced cell cycle arrest in breast cancer cell lines. Oncol Rep (2013) 0.77
A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer. BMC Cancer (2006) 0.77
Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor. Int J Clin Oncol (2015) 0.77
Current status of oral anticancer drugs in Japan. J Clin Oncol (1999) 0.76
Aromatase inhibitor strategies in metastatic breast cancer. Int J Womens Health (2010) 0.76
The Role of Combination Chemotherapy in the Treatment of Patients with Metastatic Breast Cancer. Breast Care (Basel) (2009) 0.76
The use of HRT in patients with breast cancer: yes, no, or sometimes? Br J Gen Pract (2000) 0.75
Chemotherapy with and without anthracycline. J Clin Oncol (2000) 0.75
Dose-escalation phase I study in metastatic breast cancer patients with combination of paclitaxel and tegafur·uracil. Oncol Lett (2010) 0.75
Meta-analyses of published results are unreliable. J Clin Oncol (1999) 0.75
Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer. Br J Cancer (2002) 0.75
NEO adjuvant chemotherapy in breast cancer: What have we learned so far? Indian J Med Paediatr Oncol (2010) 0.75
A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01). Br J Cancer (2001) 0.75
Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer. Eur J Cancer (2016) 0.75
Docetaxel and epirubicin salvage regimen in relapsed anthracycline-sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy. Invest New Drugs (2008) 0.75
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med (1998) 19.07
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet (2003) 8.88
Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet (2000) 8.10
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature (1994) 4.42
Consumer participation in research and health care. BMJ (1997) 3.38
What contributions do languages other than English make on the results of meta-analyses? J Clin Epidemiol (2000) 3.37
Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol (1990) 3.31
Completeness of reporting of trials published in languages other than English: implications for conduct and reporting of systematic reviews. Lancet (1996) 3.17
A quality assessment of randomized control trials of primary treatment of breast cancer. J Clin Oncol (1986) 3.14
Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest (1998) 2.97
HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A (1991) 2.83
Benefits and costs of screening and treatment for early breast cancer. Development of a basic benefit package. JAMA (1995) 2.62
Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology (1997) 2.61
Randomized clinical trials on medical treatment of glaucoma. Are they appropriate to guide clinical practice? Arch Ophthalmol (1993) 2.44
Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med (1994) 2.18
Quality, evolution, and clinical implications of randomized, controlled trials on the treatment of lung cancer. A lost opportunity for meta-analysis. JAMA (1989) 2.18
Quality of systematic reviews used in guidelines for oncology practice. Ann Oncol (2006) 2.15
Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest (1991) 2.08
T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology (1994) 2.00
Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol (2002) 2.00
Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology (2001) 1.99
Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev (2005) 1.98
Disclosure of breast cancer diagnosis: patient and physician reports. GIVIO (Interdisciplinary Group for Cancer Care Evaluation, Italy) Ann Oncol (1991) 1.87
Intrahepatic, nucleocapsid antigen-specific T cells in chronic active hepatitis B. J Immunol (1987) 1.85
Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol (1997) 1.85
Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomised controlled trials. BMJ (1998) 1.75
Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. J Virol (1993) 1.74
A European version of the Appropriateness Evaluation Protocol. Goals and presentation. The BIOMED I Group on Appropriateness of Hospital Use. Int J Technol Assess Health Care (1999) 1.73
Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med (2001) 1.73
Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS (1998) 1.70
Short stay facilities: the future of efficient paediatric emergency services. Arch Dis Child (1996) 1.64
Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol (2004) 1.62
The impact of patient management guidelines on the care of breast, colorectal, and ovarian cancer patients in Italy. Med Care (1991) 1.62
Does a drug do better when it is new? Ann Oncol (2002) 1.61
Reliability study of the European appropriateness evaluation protocol. Int J Qual Health Care (1999) 1.59
Differential diagnosis and management of focal ground-glass opacities. Eur Respir J (2008) 1.54
Incessant ovulation and ovarian cancer: a critical approach. Int J Epidemiol (1983) 1.51
Essential requirements for practice guidelines at national and local levels. Neurol Sci (2004) 1.49
The long-term prognostic significance of repeated blood pressure measurements in the elderly: SPAA (Studio sulla Pressione Arteriosa nell'Anziano) 10-year follow-up. Arch Intern Med (1999) 1.48
A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration. Diabet Med (1996) 1.46
Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer (2006) 1.46
Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. Ann Oncol (2005) 1.45
The risk of bias from omitted research. BMJ (2000) 1.43
Do specialists do it better? The impact of specialization on the processes and outcomes of care for cancer patients. Ann Oncol (1998) 1.43
The consequences of under-use of coronary revascularization; results of a cohort study in Northern Italy. Eur Heart J (2001) 1.41
The impact of cancer treatment guidelines on actual practice in Italian general hospitals: the case of ovarian cancer. Ann Oncol (1990) 1.40
Survey on the treatment of non-small-cell lung cancer in Italy. Ann Oncol (2000) 1.38
Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database Syst Rev (2004) 1.34
Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol (1999) 1.27
One model, several results: the paradox of the Hosmer-Lemeshow goodness-of-fit test for the logistic regression model. J Epidemiol Biostat (2000) 1.26
Functional characterization of cloned intrahepatic, hepatitis B virus nucleoprotein-specific helper T cell lines. J Immunol (1987) 1.25
First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer (2002) 1.24
Promoting consumers' demand for evidence-based medicine. Int J Technol Assess Health Care (1998) 1.24
Practice guidelines: useful and "participative" method? Survey of Italian physicians by professional setting. Arch Intern Med (2001) 1.22
Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol (1997) 1.21
First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. Br J Cancer (1998) 1.19
Impact of recent legislative bills regarding clinical research on Italian ethics committee activity. J Med Ethics (2008) 1.18
Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer (2003) 1.18
Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol (2009) 1.14
Selective sensitization of peripheral blood T lymphocytes to hepatitis B core antigen in patients with chronic active hepatitis type B. Clin Exp Immunol (1986) 1.14
Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res (2001) 1.13
Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev (2000) 1.13
Updating clinical recommendations for breast, colorectal and lung cancer treatments: an opportunity to improve methodology and clinical relevance. Ann Oncol (2010) 1.09
Searching for rehabilitation articles on MEDLINE and EMBASE. An example with cross-over design. Arch Phys Med Rehabil (2000) 1.09
The role of attitudes, beliefs, and personal characteristics of Italian physicians in the surgical treatment of early breast cancer. Am J Public Health (1991) 1.07
Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol (2007) 1.06
Adverse drug reactions in neonatal intensive care units. Adverse Drug React Acute Poisoning Rev (1990) 1.06
Cellular immune response to hepatitis B virus antigens. An overview. J Hepatol (1988) 1.05
Molecular features of the hepatitis B virus nucleocapsid T-cell epitope 18-27: interaction with HLA and T-cell receptor. Hepatology (1997) 1.04
Appropriateness of hospital use: an overview of Italian studies. Int J Qual Health Care (1995) 1.03
Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)). Br J Cancer (1990) 1.03
The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man. J Clin Invest (1989) 1.02
Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'. Ann Oncol (2011) 1.00
Identification of immunodominant hepatitis C virus (HCV)-specific cytotoxic T-cell epitopes by stimulation with endogenously synthesized HCV antigens. Hepatology (2001) 0.99
Psychological outcomes in women with early breast cancer. BMJ (1990) 0.99
Risk factors for pathologically confirmed benign breast disease. Am J Epidemiol (1984) 0.97
Parasitic diatoms inside antarctic sponges. Biol Bull (2000) 0.97
Role of puncture and aspiration in expectant management of simple ovarian cysts: a randomised study. BMJ (1996) 0.97
Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol (1997) 0.97
Immunopathogenesis of hepatitis C virus infection. J Hepatol (1999) 0.97
Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. Br J Anaesth (2010) 0.96
Social factors, diet and breast cancer in a northern Italian population. Br J Cancer (1984) 0.96
Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst (1982) 0.96
Impact factor and electronic versions of biomedical scientific journals. Haematologica (2001) 0.95